Literature DB >> 29162361

Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.

A Tura1, J I Bagger2, E Ferrannini3, J J Holst4, F K Knop5, T Vilsbøll6, A Mari7.   

Abstract

BACKGROUND AND AIMS: The incretin effect is impaired in type 2 diabetes (T2D), but the underlying mechanisms are only partially understood. We investigated the relationships between the time course of the incretin effect and that of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) during oral glucose tolerance tests (OGTTs), thereby estimating incretin sensitivity of the beta cell, and its associated factors. METHODS AND
RESULTS: Eight patients with T2D and eight matched subjects with normal glucose tolerance (NGT) received 25, 75, and 125 g OGTTs and corresponding isoglycemic glucose infusions (IIGI). The time course of the incretin effect, representing potentiation of insulin secretion by incretins (PINCR), was determined by mathematical modelling as the time-dependent fold increase in insulin secretion during OGTT compared to IIGI. The time course of PINCR was correlated with that of both GIP and GLP-1 in each subject (median r = 0.67 in NGT and 0.45 in T2D). We calculated an individual beta cell sensitivity to incretins (SINCR) using a weighted average of GIP and GLP-1 (pooled incretin concentration, PIC), as the slope of the relationship between PINCR and PIC. SINCR was reduced in T2D (p < 0.01). In the whole group, mean PIC, GIP and GLP-1 concentrations during the OGTT were inversely correlated with SINCR, but T2D had lower PIC, GIP and GLP-1 levels at the same SINCR (p < 0.05).
CONCLUSION: Relative incretin insensitivity is partly compensated for by higher incretin secretory responses. However, T2D shows both impairment in incretin sensitivity and abnormal compensation by incretin secretion.
Copyright © 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glucagon-like Peptide-1; Glucose-dependent insulinotropic peptide; Incretin effect; Incretin sensitivity; Insulin secretion; Mathematical model; Oral glucose tolerance test; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 29162361     DOI: 10.1016/j.numecd.2017.10.006

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  9 in total

1.  Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.

Authors:  Brenno Astiarraga; Valéria B Chueire; Aglécio L Souza; Ricardo Pereira-Moreira; Sarah Monte Alegre; Andrea Natali; Andrea Tura; Andrea Mari; Ele Ferrannini; Elza Muscelli
Journal:  Diabetologia       Date:  2018-05-07       Impact factor: 10.122

Review 2.  Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.

Authors:  Laleh Razavi-Nematollahi; Faramarz Ismail-Beigi
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810

3.  Impact of short-term exercise training intensity on β-cell function in older obese adults with prediabetes.

Authors:  Steven K Malin; Monique E Francois; Natalie Z M Eichner; Nicole M Gilbertson; Emily M Heiston; Chiara Fabris; Marc Breton
Journal:  J Appl Physiol (1985)       Date:  2018-10-11

Review 4.  Mathematical Modeling for the Physiological and Clinical Investigation of Glucose Homeostasis and Diabetes.

Authors:  Andrea Mari; Andrea Tura; Eleonora Grespan; Roberto Bizzotto
Journal:  Front Physiol       Date:  2020-11-25       Impact factor: 4.566

5.  Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test.

Authors:  Micaela Morettini; Laura Burattini; Christian Göbl; Giovanni Pacini; Bo Ahrén; Andrea Tura
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

6.  Insulin clearance and incretin hormones following oral and "isoglycemic" intravenous glucose in type 2 diabetes patients under different antidiabetic treatments.

Authors:  Andrea Tura; Christian Göbl; Irfan Vardarli; Giovanni Pacini; Michael Nauck
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.379

7.  A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment.

Authors:  Vijaya Subramanian; Jonatan I Bagger; Jens J Holst; Filip K Knop; Tina Vilsbøll
Journal:  Front Physiol       Date:  2022-09-06       Impact factor: 4.755

8.  Mathematical model of insulin kinetics accounting for the amino acids effect during a mixed meal tolerance test.

Authors:  Micaela Morettini; Maria Concetta Palumbo; Christian Göbl; Laura Burattini; Yanislava Karusheva; Michael Roden; Giovanni Pacini; Andrea Tura
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

Review 9.  Biomarkers for type 2 diabetes.

Authors:  Markku Laakso
Journal:  Mol Metab       Date:  2019-09       Impact factor: 7.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.